Role of IL-24 in NK cell activation and its clinical implication in systemic lupus erythematosus

Clinical Rheumatology - Interleukin (IL)-24 has been considered as an inflammatory cytokine in autoimmune diseases. However, conflicting data exist and its biological function remains...     

Uncoupling protein 3 genetic variants in human obesity: the c-55t promoter polymorphism is negatively correlated with body mass index in a UK Caucasian population

OBJECTIVE: To investigate whether genetic variation at the UCP3 locus contributes to human obesity. SUBJECTS: Ninety-one obese children (BMI>4 standard deviations from age related mean) and 419 Caucasian adults from the Isle of Ely Study. DESIGN: Single strand conformation polymorphism (SSCP) analysis was used to scan the coding region of the UCP3 gene in 91 severely obese children. A common polymorphism identified in this gene (c-55t) has been shown to associate with lower UCP3 mRNA expression. Polymerase chain reaction-based forced restriction digestion was used to detect this allele in Caucasian adults. Multiple regression analysis was used to determine associations between the c-55t genotype and anthropometric, energetic and biochemical indices relevant to obesity. MEASUREMENTS: For the obese children, SSCP analysis and sequencing of variants were carried out. For the Isle of Ely Study, c-55t genotype and anthropometric (body mass index, waist-hip ratio, percentage body fat), energetic (dietary fat intake, physical activity index, adjusted metabolic rate, maximum oxygen consumption) and biochemical indices (pre- and post-glucose challenge plasma triglycerides, non-esterified fatty acids, insulin and glucose) were determined. RESULTS: A previously reported missense mutation (V102I) was detected in a single obese Afro-Carribean child. Twenty-one percent of the genes examined in the Isle of Ely study carried the c-55t promoter variant. Age-adjusted body mass index (BMI) was significantly (P=0.0037) lower in carriers of this variant. CONCLUSION: Mutations in the coding sequence of UCP3 are unlikely to be a common monogenic cause of severe human obesity. In a Caucasian population the UCP3 c-55t polymorphism is negatively associated with BMI.     

朱丹溪气郁用药规律研究

目的:探究朱丹溪气郁的用药规律及其对临床的指导意义.方法:以《朱丹溪医学全书》作为方剂的基本信息来源,收集书中所涉所有相关方剂,运用excel将书中所有涉及方药进行数据库录入,建立数据库,通过数据挖掘技术对药物类别、使用频次、归经、性味进行统计.结果:朱丹溪著作共涉及治气方剂914个,其中出现频数大于100的常用药物有16味,分别是炙甘草、人参、白术、茯苓、陈皮、生姜、当归、香附、白芍、半夏、川芎等;在药物类别上补虚药和理气药使用频次最高;按药性划分使用频率较高依次为温性药57.29％、平性药22.24％、寒性药占20.48％;按归经划分使用频次较高的依次为脾经26.63％、肺经15.68％、胃经13.36％、心经占12.07％;按药味划分使用频次较高依次为苦味药36.27％、辛味药30.03％、甘味药29.46％,酸味药4.23％.结论:朱丹溪在治疗气证时,擅长应用炙甘草,以四君子汤为主方,配以补虚药,补母益子;同时,朱丹溪治气还往往佐以治血、治痰,扶正祛邪.通过对统计结果进行比较发现,朱丹溪在治气药物归经偏于脾胃两经,重视中焦脾胃之气的升提作用.     

阿托伐他汀在缺血性卒中患者中的疗效研究

目的探讨阿托伐他汀对缺血性卒中患者的疗效。方法收集2012年6月~2014年2月来我院诊治的缺血性卒中患者311例为研究对象,依据其来诊的顺序随机分为实验组与对照组。两组均给予常规内科治疗,实验组加用阿托伐他汀治疗,治疗3个月后,观察两组的治疗效果。结果实验组的临床疗效明显高于对照组;治疗后实验组的总胆固醇、甘油三酯及低密度脂蛋白明显低于对照组,而高密度脂蛋白明显高于对照组。结论阿托伐他汀可以改善缺血性卒中患者血脂水平,提高缺血性卒中患者的治疗效果。